Cue Biopharma (NASDAQ:CUE) Rating Lowered to Hold at Wall Street Zen

Posted by Geri Gentry on Aug 17th, 2026

Cue Biopharma (NASDAQ:CUE – Get Free Report) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Cue Biopharma

Cue Biopharma Stock Performance

Shares of CUE stock opened at $34.20 on Friday. Cue Biopharma has a 52-week low of $4.97 and a 52-week high of $45.50. The stock has a market cap of $143.64 million, a price-to-earnings ratio of -1.27 and a beta of 2.47. The firm’s 50-day moving average is $29.50 and its 200-day moving average is $146.00.

Cue Biopharma (NASDAQ:CUE – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 482.58%. The business had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million.

Insider Buying and Selling at Cue Biopharma

In related news, CEO Shao-Lee Lin sold 18,258 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96. Following the sale, the chief executive officer owned 705,995 shares in the company, valued at approximately $20,205,576.90. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 14.56% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. bought a new position in shares of Cue Biopharma in the second quarter worth about $83,000. Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma during the second quarter worth $389,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cue Biopharma during the second quarter worth $722,000. ADAR1 Capital Management LLC bought a new position in shares of Cue Biopharma in the 2nd quarter valued at $1,742,000. Finally, BlackRock Inc. bought a new position in shares of Cue Biopharma in the 2nd quarter valued at $1,824,000. Institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

(Get Free Report)

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.